Login to Your Account

My, my American pie: Xencor's Novartis pact slices nicely, up to $2.4B+ for non-U.S. rights

By Randy Osborne
Staff Writer

Tuesday, June 28, 2016

Xencor Inc.'s broadly enabling platform made possible "the calculated trade-off" by Novartis AG that let his bispecific antibody firm hang onto U.S. rights for its pair of lead compounds in a deal that could be worth as much as $2.4 billion-plus.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription